Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3620]

ASCO GI: Trifluridine/tipiracil plus bevacizumab improves OS for third line mCRC

ASCO GI: Trifluridine/tipiracil plus bevacizumab improves OS for third line mCRC

Neoadjuvant immunotherapy leads to low recurrence in localised mismatch repair–deficient colorectal cancer

Neoadjuvant immunotherapy leads to low recurrence in localised mismatch repair–deficient colorectal cancer

Scientists detail major mechanism lung cancers use to evade immune attack

Scientists detail major mechanism lung cancers use to evade immune attack

Drug combo breaks down cancer resistance to immunotherapy

Drug combo breaks down cancer resistance to immunotherapy

Enhanced cancer immunotherapies through cytokine-labeled T cells

Enhanced cancer immunotherapies through cytokine-labeled T cells

Study uncovers novel aspect of tumour evolution and potential targets for therapy

Study uncovers novel aspect of tumour evolution and potential targets for therapy

Clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma

Clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma

Cellular messengers improve cancer therapy

Cellular messengers improve cancer therapy

World's first clinical trial with CAR-T technology for patients with T-cell leukaemia subtype authorised

World's first clinical trial with CAR-T technology for patients with T-cell leukaemia subtype authorised

FDA grants approval to atezolizumab for alveolar soft part sarcoma

FDA grants approval to atezolizumab for alveolar soft part sarcoma

More from ecancer